Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eptacog Beta→

Eptacog Beta PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1851951-40-0
Molecular formula
C2077H3172N582O629S31
Molecular weight
~50000 g/mol
Drug class
Recombinant activated human coagulation factor VIIa (rFVIIabypassing haemostatic agent)
Mechanism of action
Activated factor VII promotes haemostasis by binding tissue factor and activating factor X, increasing thrombin generation and fibrin formation through a pathway that can bypass deficient or inhibited factor VIII or IX.
Indications / reported uses
  • Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in adults and adolescents aged 12 years or older with congenital haemophilia and inhibitors to factor VIII or IX, or expected poor response to factor replacement, under the Cevenfacta authorisation

Sources: EMA Cevenfacta EPAR · EMA overview · US FDA Sevenfact page

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant activated human coagulation factor VIIa (rFVIIa; bypassing haemostatic agent)

Mechanism of action

Activated factor VII promotes haemostasis by binding tissue factor and activating factor X, increasing thrombin generation and fibrin formation through a pathway that can bypass deficient or inhibited factor VIII or IX.

General use cases

  • Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in adults and adolescents aged 12 years or older with congenital haemophilia and inhibitors to factor VIII or IX, or expected poor response to factor replacement, under the Cevenfacta authorisation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Eptacog Beta PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eptacog Beta Permitted Daily Exposure (PDE) report (the Eptacog Beta PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eptacog Beta Occupational Exposure Limit (OEL) report (the Eptacog Beta OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.